Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. Advertisement cookies are used to provide visitors with customized advertisements. 

Embodied values: post-pharmaceutical health and the accumulation of surplus vitality in regenerative stem cell medicine

Embodied values: post-pharmaceutical health and the accumulation of surplus vitality in regenerative stem cell medicine

Christian Haddad
Affiliated Researcher

Haddad, Christian (2019): Embodied values: Post-pharmaceutical health and the accumulation of surplus vitality in regenerative stem cell medicine. In: Sociologias Vol. 21 (50), p. 48-79. (peer-reviewed)

Abstract
This paper analyzes an emerging form of post-pharmaceutical health and its
underlying regime of value in the global bioeconomy of regenerative stem cell-based medicine (RSCM). Animated by a vision to overcome drug-based therapies and their underlying political economies, RSCM pursues a form of regenerative health that is strikingly at odds with pharmaceutical regimes of drug research, regulation and therapy. To offer a theoretical account of these competing forms of health, the paper provides an analysis of the regimes of values that underpin pharmaceutical and regenerative health respectively. This analysis is done alongside three dimensions: the interlinkage between knowledge, technology and economic value creation; its relation to normative values and ethics; and conceptions and valuations of the biomedical subject and his/her body in biomedical research, intervention and innovation. Contrasting these two diverging regimes of health and value suggests that in RSCM the pharmaceutical logic of accumulating “surplus health” is not entirely dismissed but re-articulated in a regime based on the (re-)generation of regenerative biovalue through the extraction and ex vivo accumulation of “surplus vitality”. Finally, the article discusses “post-pharmaceutical health” as a sensitizing concept that offers new research avenues into emergent forms of health, value, and subjectivity beyond RSCM.

Keywords
Bioeconomy, Biovalue, Health regimes, Pharmaceuticals, Regenerative stem cell medicine, Regulatory pharmaceuticalization.